Research Paper Volume 15, Issue 7 pp 2373—2394

Characterization of the HDAC/PI3K inhibitor CUDC-907 as a novel senolytic

class="figure-viewer-img"

Figure 3. Investigation of the pathways involved in the senolytic effects of CUDC-907. Cell viability of control and senescent EJp53, H522 and HCT116 treated with different concentrations of dactolisib, panobinostat, buparlisib or CI-994 for 72h, as measured by a CTG assay. All values show mean ±SD of three independent experiments, and P values between each control and senescence pair are shown as *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.